Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biopharma News
Biosimilar Deals 2025
Biosimilar Deals 2026
Biosimilars Deals 2023
Biosimilars Deals 2024
Chantal Savage
Diversity
Helen Macpherson
Intranet
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Sally Paterson
Trade Marks
Webinars

Expanded Indication for Celltrion’s Biosimilar Ustekinumab Recommended in Europe

Nov 9, 2026

On 9 November 2026, Celltrion announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for an expanded indication for Steqeyma®, biosimilar to Janssen’s Stelara® (ustekinumab), to treat Crohn’s disease and ulcerative colitis in children aged two and older.

Steqeyma® is already approved in Europe for Crohn’s disease in paediatric patients weighing at least 40 kilograms, as well as for adult Crohn’s disease and ulcerative colitis.  It is also approved for plaque psoriasis in adults and children and psoriatic arthritis in adults.

Celltrion has launched Steqeyma® in Europe (November 2024), the US (March 2025), Japan (July 2025) and Australia (listed on the PBS from 1 August 2025).